Orphanet Journal of Rare Diseases (2020-10-01)

Creation and implementation of a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC registry)

  • Tomàs Pinós,
  • Antoni L. Andreu,
  • Claudio Bruno,
  • Georgios M. Hadjigeorgiou,
  • Ronald G. Haller,
  • Pascal Laforêt,
  • Alejandro Lucía,
  • Miguel A. Martín,
  • Andrea Martinuzzi,
  • Carmen Navarro,
  • Piraye Oflazer,
  • Jean Pouget,
  • Ros Quinlivan,
  • Sabrina Sacconi,
  • Renata S. Scalco,
  • Antonio Toscano,
  • John Vissing,
  • Matthias Vorgerd,
  • Andrew Wakelin,
  • Ramon Martí,
  • EUROMAC Consortium

DOI
https://doi.org/10.1186/s13023-020-01455-z
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background International patient registries are of particular importance for rare disorders, as they may contribute to overcome the lack of knowledge derived from low number of patients and limited awareness of these diseases, and help to learn more about their geographical or population-based specificities, which is relevant for research purposes and for promoting better standards of care and diagnosis. Our objective was to create and implement a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC) and to disseminate the knowledge of these disorders. Results Teams from nine different countries (United Kingdom, Spain, Italy, France, Germany, Denmark, Greece, Turkey and USA) created a consortium that developed the first European registry dedicated to rare muscle glycogenoses. A work plan was implemented to design the database and platform that constitute the registry, by choosing clinical, genetics and molecular variables of interest, based on experience gained from previous national registries for similar metabolic disorders. Among dissemination activities, several teaching events were organized in different countries, especially those where the consortium considered the awareness of these diseases needs to be promoted among health professionals and patients. Conclusion EUROMAC represents a step forward in the knowledge of those disorders to which it is dedicated, and will have relevant clinical outcomes at the diagnostic, epidemiological, clinical and research level.

Keywords